Researchers report early findings that renal denervation's benefit to heart health may be independent of its treatment of hypertension, opening the door for novel indications for the technology.
MASSDEVICE ON CALL — Renal denervation, studied primarily in treatment of hypertension, may product benefits to heart health independent of those generated by lowering blood pressure, according to researchers reporting results from a small study.
The clinicians cautioned that the results are very early and need confirmation from a larger study, but were worked up about the findings.
Medtech titan Medtronic wins European and Australian regulatory approval for next-generation components of its Symplicity renal denervation treatment for drug-resistant hypertension.
Renal stenting should never be the 1st line of attack for treating patients with hypertension and renal-artery stenosis, according to results from the CORAL clinical trial that were presented during today's American Heart Assn. Scientific Sessions.
The highly anticipated results from the CORAL clinical trial wasn't great news for renal stents, as researchers reported that renal-artery stenting offered "no benefits" over drugs alone in treating patients with atherosclerotic renal-artery stenosis and elevated blood pressure, chronic kidney disease, or both.
Medtronic enrolls the 1st patient in an FDA-approved clinical trial evaluating renal denervation in treatment of patients with less-severe drug-resistant hypertension.
Medical device giant Medtronic (NYSE:MDT) is making fast work of its U.S. renal denervation program, today announcing FDA approval to begin enrolling lower-risk patients in the next phase of its SYMPLICITY clinical trials.
Renal denervation has won a lot of praise as a potential solution for patients with resistant hypertension, but the excessive celebration of early clinical trial results may be setting everyone up for a major letdown and a harsh backlash. This week cardiologists at the Transcatheter Cardiovascular Therapeutics conference, including those involved with Medtronic's and Boston Scientific's clinical trials, warned of the dangers of exaggeration.
Renal denervation is still in its youth, but the limited clinical trials and lack of substantial confirmation hasn't curbed much of the hype for the technology as a means of treating patients with resistant hypertension.
Boston Scientific says its Vessix renal denervation system continues to generate significant and sustained reduction in blood pressure in an updated analysis of the REDUCE-HTN clinical trial.
Researchers and physicians at the Transcatheter Cardiovascular Therapeutics symposium discuss renal denervation in helping alleviate symptoms of everything from congestive heart failure to obstructive sleep apnea.
Renal denervation may have lost some of its hype over the course of the last year, but researchers are still findings new ways to utilize the technology to target new diseases.